Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer von Sihag, Smita, Ku, Geoffrey Y., Tan, Kay See, Nussenzweig, Samuel, Wu, Abraham, Janjigian, Yelena Y., Jones, David R., Molena, Daniela

Volltext

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial von Janjigian, Yelena Y, Maron, Steven B, Chatila, Walid K, Millang, Brittanie, Chavan, Shweta S, Alterman, Carly, Chou, Joanne F, Segal, Michal F, Simmons, Marc Z, Momtaz, Parisa, Shcherba, Marina, Ku, Geoffrey Y, Zervoudakis, Alice, Won, Elizabeth S, Kelsen, David P, Ilson, David H, Nagy, Rebecca J, Lanman, Richard B, Ptashkin, Ryan N, Donoghue, Mark T A, Capanu, Marinela, Taylor, Barry S, Solit, David B, Schultz, Nikolaus, Hechtman, Jaclyn F

Volltext

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer von Janjigian, Yelena Y, Sanchez-Vega, Francisco, Jonsson, Philip, Chatila, Walid K, Hechtman, Jaclyn F, Ku, Geoffrey Y, Riches, Jamie C, Tuvy, Yaelle, Kundra, Ritika, Bouvier, Nancy, Vakiani, Efsevia, Gao, Jianjiong, Heins, Zachary J, Gross, Benjamin E, Kelsen, David P, Zhang, Liying, Strong, Vivian E, Schattner, Mark, Gerdes, Hans, Coit, Daniel G, Bains, Manjit, Stadler, Zsofia K, Rusch, Valerie W, Jones, David R, Molena, Daniela, Shia, Jinru, Robson, Mark E, Capanu, Marinela, Middha, Sumit, Zehir, Ahmet, Hyman, David M, Scaltriti, Maurizio, Ladanyi, Marc, Rosen, Neal, Ilson, David H, Berger, Michael F, Tang, Laura, Taylor, Barry S, Solit, David B, Schultz, Nikolaus

Volltext

Role of Imaging in Esophageal Cancer Management in 2020: Update for Radiologists von Jayaprakasam, Vetri Sudar, Yeh, Randy, Ku, Geoffrey Y, Petkovska, Iva, Fuqua, 3rd, James L, Gollub, Marc, Paroder, Viktoriya

Volltext

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience von Glassman, Danielle C, Palmaira, Randze L, Covington, Christina M, Desai, Avni M, Ku, Geoffrey Y, Li, Jia, Harding, James J, Varghese, Anna M, O'Reilly, Eileen M, Yu, Kenneth H

Volltext

Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter? von Sihag, Smita, Nobel, Tamar, Hsu, Meier, De La Torre, Sergio, Tan, Kay See, Janjigian, Yelena Y., Ku, Geoffrey Y., Tang, Laura H., Wu, Abraham J., Maron, Steven B., Bains, Manjit S., Jones, David R., Molena, Daniela

Volltext

Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence von Nakauchi, Masaya, Vos, Elvira, Tang, Laura H., Gonen, Mithat, Janjigian, Yelena Y., Ku, Geoffrey Y., Ilson, David H., Maron, Steven B., Yoon, Sam S., Brennan, Murray F., Coit, Daniel G., Strong, Vivian E.

Volltext

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit von Yuan, Jianda, Gnjatic, Sacha, Li, Hao, Powel, Sarah, Gallardo, Humilidad F, Ritter, Erika, Ku, Geoffrey Y, Jungbluth, Achim A, Segal, Neil H, Rasalan, Teresa S, Manukian, Gregor, Xu, Yinyan, Roman, Ruth-Ann, Terzulli, Stephanie L, Heywood, Melanie, Pogoriler, Evelina, Ritter, Gerd, Old, Lloyd J, Allison, James P, Wolchok, Jedd D

Volltext

Clinical Utility of 18F-2-Fluoro-deoxy-d-glucose PET Imaging in Locally Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma von Cowzer, Darren, Keane, Fergus, Ku, Geoffrey Y.

Volltext

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer von Janjigian, Yelena Y, Vakiani, Efsevia, Ku, Geoffrey Y, Herrera, Jessica M, Tang, Laura H, Bouvier, Nancy, Viale, Agnès, Socci, Nicholas D, Capanu, Marinela, Berger, Michael, Ilson, David H

Volltext

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials von Ku, Geoffrey Y, Haaland, Benjamin A, de Lima Lopes, Gilberto

Volltext

Systemic therapy for esophageal cancer: chemotherapy von Ku, Geoffrey Y.

Volltext

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer von Mondaca, Sebastian, Margolis, Matthew, Sanchez-Vega, Francisco, Jonsson, Philip, Riches, Jamie C., Ku, Geoffrey Y., Hechtman, Jaclyn F., Tuvy, Yaelle, Berger, Michael F., Shah, Manish A., Kelsen, David P., Ilson, David H., Yu, Kenneth, Goldberg, Zoe, Epstein, Andrew S., Desai, Avni, Chung, Vincent, Chou, Joanne F., Capanu, Marinela, Solit, David B., Schultz, Nikolaus, Janjigian, Yelena Y.

Volltext

Tumor mutational load predicts survival after immunotherapy across multiple cancer types von Samstein, Robert M., Lee, Chung-Han, Shoushtari, Alexander N., Hellmann, Matthew D., Shen, Ronglai, Janjigian, Yelena Y., Barron, David A., Zehir, Ahmet, Jordan, Emmet J., Omuro, Antonio, Kaley, Thomas J., Kendall, Sviatoslav M., Motzer, Robert J., Hakimi, A. Ari, Voss, Martin H., Russo, Paul, Rosenberg, Jonathan, Iyer, Gopa, Bochner, Bernard H., Bajorin, Dean F., Al-Ahmadie, Hikmat A., Chaft, Jamie E., Rudin, Charles M., Riely, Gregory J., Baxi, Shrujal, Ho, Alan L., Wong, Richard J., Pfister, David G., Wolchok, Jedd D., Barker, Christopher A., Gutin, Philip H., Brennan, Cameron W., Tabar, Viviane, Mellinghoff, Ingo K., DeAngelis, Lisa M., Ariyan, Charlotte E., Lee, Nancy, Tap, William D., Gounder, Mrinal M., D’Angelo, Sandra P., Saltz, Leonard, Stadler, Zsofia K., Scher, Howard I., Baselga, Jose, Razavi, Pedram, Klebanoff, Christopher A., Yaeger, Rona, Segal, Neil H., Ku, Geoffrey Y., DeMatteo, Ronald P., Ladanyi, Marc, Rizvi, Naiyer A., Berger, Michael F., Riaz, Nadeem, Solit, David B., Chan, Timothy A., Morris, Luc G. T.

Volltext

Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters von Ku, Geoffrey Y., Haaland, Benjamin A., de Lima Lopes, Gilberto

Volltext

Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers von Park, Do Joong, Yoon, Changhwan, Thomas, Nicholas, Ku, Geoffrey Y., Janjigian, Yelena Y., Kelsen, David P., Ilson, David H., Goodman, Karyn A., Tang, Laura H., Strong, Vivian E., Coit, Daniel G., Yoon, Sam S.

Volltext

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway von Ku, Geoffrey Y

Volltext

Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer von Vellayappan, Balamurugan A, Soon, Yu Yang, Ku, Geoffrey Y, Leong, Cheng Nang, Lu, Jiade J, Tey, Jeremy CS, Vellayappan, Balamurugan A

Volltext

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma von Kelly, Ronan J, Lee, Jeeyun, Bang, Yung-Jue, Almhanna, Khaldoun, Blum-Murphy, Mariela, Catenacci, Daniel V T, Chung, Hyun Cheol, Wainberg, Zev A, Gibson, Michael K, Lee, Keun-Wook, Bendell, Johanna C, Denlinger, Crystal S, Chee, Cheng Ean, Omori, Takeshi, Leidner, Rom, Lenz, Heinz-Josef, Chao, Yee, Rebelatto, Marlon C, Brohawn, Philip Z, He, Peng, McDevitt, Jennifer, Sheth, Siddharth, Englert, Judson M, Ku, Geoffrey Y

Volltext

Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer von Greally, Megan, Chou, Joanne F, Chatila, Walid K, Margolis, Matthew, Capanu, Marinela, Hechtman, Jaclyn F, Tuvy, Yaelle, Kundra, Ritika, Daian, Foysal, Ladanyi, Marc, Kelsen, David P, Ilson, David H, Berger, Michael F, Tang, Laura H, Solit, David B, Diaz, Jr, Luis A, Schultz, Nikolaus, Janjigian, Yelena Y, Ku, Geoffrey Y

Volltext